Sebastian Krossa

Sebastian Krossa

Auto-generated profile, based on publicly available information

Sebastian Krossa

Department of Circulation and Medical imaging, Norwegian University of Science and Technology, Trondheim, Norway.

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAntti Kiviaho
Antti Kiviaho
SESini K. Eerola
Sini K. Eerola
HKHeini M. L. Kallio
Heini M. L. Kallio
MAMaria Karoline Andersen
Maria Karoline Andersen
MHMiina Hoikka
Miina Hoikka
MNMatti Nykter
Matti Nykter
Prostate cancer treatment resistance is a significant challenge facing the field. Genomic and transcriptomic profiling have partially elucidated the mechanisms through which cancer cells escape treatment, but their relation toward the tumor microenvironment (TME) remains elusive. Here we present a comprehensive transcriptomic landscape of the prostate TME at multiple points in the standard treatment timeline employing single-cell RNA-sequencing and spatial transcriptomics data from 120 patients. We identify club-like cells as a key epithelial cell subtype that acts as an interface between the prostate and the immune system. Tissue areas enriched with club-like cells have depleted androgen signaling and upregulated expression of luminal progenitor cell markers. Club-like cells display a senescence-associated secretory phenotype and their presence is linked to increased polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) activity. Our results indicate that club-like cells are associated with myeloid inflammation previously linked to androgen deprivation therapy resistance, providing a rationale for their therapeutic targeting.

16 February 2022 in Proteomics
Verified
Journal Article
Open access
PDF file
THTherese S. Høiem
Therese S. Høiem
MAMaria Karoline Andersen
Maria Karoline Andersen
Marta Martín-LorenzoMarta Martín-Lorenzo
Marta Martín-Lorenzo
Rémi LonguespéeRémi Longuespée
Rémi Longuespée
BCBritt S.R. Claes
Britt S.R. Claes
MTMay‐Britt Tessem
May‐Britt Tessem
MALDI MS imaging (MSI) is a powerful analytical tool for spatial peptide detection in heterogeneous tissues. Proper sample preparation is crucial to achieve high quality, reproducible measurements. Here we developed an optimized protocol for spatially resolved proteolytic peptide detection with MALDI time‐of‐flight MSI of fresh frozen prostate tissue sections. The parameters tested included four different tissue washes, four methods of protein denaturation, four methods of trypsin digestion (different trypsin densities, sprayers, and incubation times), and five matrix deposition methods (different sprayers, settings, and matrix concentrations). Evaluation criteria were the number of detected and excluded peaks, percentage of high mass peaks, signal‐to‐noise ratio, spatial localization, and average intensities of identified peptides, all of which were integrated into a weighted quality evaluation scoring system. Based on these scores, the optimized protocol included an ice‐cold EtOH+H 2 O wash, a 5 min heating step at 95°C, tryptic digestion incubated for 17h at 37°C and CHCA matrix deposited at a final amount of 1.8 μg/mm 2 . Including a heat‐induced protein denaturation step after tissue wash is a new methodological approach that could be useful also for other tissue types. This optimized protocol for spatial peptide detection using MALDI MSI facilitates future biomarker discovery in prostate cancer and may be useful in studies of other tissue types.

16 January 2020 in Analytical Chemistry
Verified
Journal Article
Open access
MAMaria Karoline Andersen
Maria Karoline Andersen
SKSebastian Krossa
Sebastian Krossa
THTherese S. Høiem
Therese S. Høiem
RBRebecca Buchholz
Rebecca Buchholz
BCBritt S. R. Claes
Britt S. R. Claes
MTMay-Britt Tessem
May-Britt Tessem
Levels of zinc, along with its mechanistically related metabolites citrate and aspartate, are widely reported as reduced in prostate cancer compared to healthy tissue and are therefore pointed out as potential cancer biomarkers. Previously, it has only been possible to analyze zinc and metabolites by separate detection methods. Through matrix-assisted laser desorption/ionization mass spectrometry imaging (MSI), we were for the first time able to demonstrate, in two different sample sets (n = 45 and n = 4), the simultaneous spatial detection of zinc, in the form of ZnCl3–, together with citrate, aspartate, and N-acetylaspartate on human prostate cancer tissues. The reliability of the ZnCl3– detection was validated by total zinc determination using laser ablation inductively coupled plasma MSI on adjacent serial tissue sections. Zinc, citrate, and aspartate were correlated with each other (range r = 0.46 to 0.74) and showed a significant reduction in cancer compared to non-cancer epithelium (p < 0.05, log2 fold change range: −0.423 to −0.987), while no significant difference between cancer and stroma tissue was found. Simultaneous spatial detection of zinc and its metabolites is not only a valuable tool for analyzing the role of zinc in prostate metabolism but might also provide a fast and simple method to detect zinc, citrate, and aspartate levels as a biomarker signature for prostate cancer diagnostics and prognostics.

21 January 2016 in eLife
Verified
Journal Article
Open access
KHKirsten Hattermann
Kirsten Hattermann
HGHenrike Gebhardt
Henrike Gebhardt
SKSebastian Krossa
Sebastian Krossa
ALAndreas Ludwig
Andreas Ludwig
RLRalph Lucius
Ralph Lucius
RMRolf Mentlein
Rolf Mentlein
The transmembrane chemokines CX3CL1/fractalkine and CXCL16 are widely expressed in different types of tumors, often without an appropriate expression of their classical receptors. We observed that receptor-negative cancer cells could be stimulated by the soluble chemokines. Searching for alternative receptors we detected that all cells expressing or transfected with transmembrane chemokine ligands bound the soluble chemokines with high affinity and responded by phosphorylation of intracellular kinases, enhanced proliferation and anti-apoptosis. This activity requires the intracellular domain and apparently the dimerization of the transmembrane chemokine ligand. Thus, shed soluble chemokines can generate auto- or paracrine signals by binding and activating their transmembrane forms. We term this novel mechanism “inverse signaling”. We suppose that inverse signaling is an autocrine feedback and fine-tuning system in the communication between cells that in tumors supports stabilization and proliferation.

8 November 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
MAMaria Karoline Andersen
Maria Karoline Andersen
SKSebastian Krossa
Sebastian Krossa
EMElise Midtbust
Elise Midtbust
CPChristine A. Pedersen
Christine A. Pedersen
MWMaximilian Wess
Maximilian Wess
MTMay-Britt Tessem
May-Britt Tessem
Prostate tumor heterogeneity is a major obstacle when studying the biological mechanisms of molecular markers. Increased gene expression levels of secreted frizzled-related protein 4 (SFRP4) is a biomarker in aggressive prostate cancer. To understand how SFRP4 relates to prostate cancer we performed comprehensive spatial and multiomics analysis of the same prostate cancer tissue samples. The experimental workflow included spatial transcriptomics, bulk transcriptomics, proteomics, DNA methylomics and tissue staining. SFRP4 mRNA was predominantly located in cancer stroma, produced by fibroblasts and smooth muscle cells, and co-expressed with extracellular matrix components. We also confirmed that higher SFRP4 gene expression is associated with cancer aggressiveness. Gene expression of SFRP4 was affected by gene promotor methylation. Surprisingly, the high mRNA levels did not reflect SFRP4 protein levels, which was much lower. This study contributes previously unknown insights of SFRP4 mRNA in the prostate tumor environment that potentially can improve diagnosis and treatment.

18 April 2015 in Oncotarget
Verified
Journal Article
Open access
SKSebastian Krossa
Sebastian Krossa
ASAnne Dorothée Schmitt
Anne Dorothée Schmitt
KHKirsten Hattermann
Kirsten Hattermann
JFJürgen Fritsch
Jürgen Fritsch
ASAxel J. Scheidig
Axel J. Scheidig
JHJanka Held-Feindt
Janka Held-Feindt
Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1 Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1